Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

RAD001 – Anti-Cancer Therapy, Anti-neoplastic agent by Novartis

Drug (Brand/Generic)

Afinitor (formerly RAD001)/ everolimus

Company/Licensee

Novartis

Therapy Class

Anti-neoplastic agent

Product Description

mTOR inhibitor

Current Indication

Renal cell carcinoma, subependymal giant cell astrocytoma

Market Sector

Oncology

Development Status

Approved in the US, Europe, Japan and Switzerland
Expand
Close
Close
Close

Go Top